Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,066 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sirtuins and inflammation: Friends or foes?
Gallí M, Van Gool F, Leo O. Gallí M, et al. Biochem Pharmacol. 2011 Mar 1;81(5):569-76. doi: 10.1016/j.bcp.2010.12.010. Epub 2010 Dec 22. Biochem Pharmacol. 2011. PMID: 21184744 Review.
[A new inflammatory pathway linked to NAD].
Van Gool F, Galli M, Rongvaux A, Andris F, Leo O. Van Gool F, et al. Among authors: galli m. Med Sci (Paris). 2009 Jun-Jul;25(6-7):551-3. doi: 10.1051/medsci/2009256-7551. Med Sci (Paris). 2009. PMID: 19602344 Free article. French. No abstract available.
Shaping the Emission Directivity of Single Quantum Dots in Dielectric Nanodisks Exploiting Mie Resonances.
Cruciano C, Rocco D, Genco A, Tognazzi A, Locatelli A, Carletti L, Fedorov A, Trovatello C, Di Blasio G, Bargigia I, Louca C, Gubian P, Tavani G, Lovisolo L, Tuktamyshev A, Andreani LC, Galli M, Cerullo G, Leo G, Sanguinetti S, De Angelis C, Bollani M. Cruciano C, et al. Among authors: galli m. ACS Nano. 2025 Jan 11. doi: 10.1021/acsnano.4c13327. Online ahead of print. ACS Nano. 2025. PMID: 39797816
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients.
Martino EA, Palmieri S, Galli M, Derudas D, Mina R, Della Pepa R, Zambello R, Vigna E, Bruzzese A, Mangiacavalli S, Zamagni E, Califano C, Musso M, Conticello C, Cerchione C, Mele G, Di Renzo N, Offidani M, Tarantini G, Casaluci GM, Rago A, Ria R, Uccello G, Barilà G, Palumbo G, Pettine L, De Magistris C, Vincelli ID, Brunori M, Accardi F, Amico V, Amendola A, Fontana R, Bongarzoni V, Rossini B, Cotzia E, Gozzetti A, Rizzi R, Sgherza N, Curci P, Mancuso K, Reddiconto G, Maroccia A, Franceschini L, Bertuglia G, Nappi D, Barbieri E, Quaresima M, Petrucci MT, Di Raimondo F, Neri A, Tripepi G, Musto P, Morabito F, Gentile M. Martino EA, et al. Among authors: galli m. ESMO Open. 2025 Jan 7;10(2):104084. doi: 10.1016/j.esmoop.2024.104084. Online ahead of print. ESMO Open. 2025. PMID: 39778329 Free article.
Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial.
Richardson P, Beksaç M, Oriol A, Lindsay J, Schjesvold F, Galli M, Yağcı M, Larocca A, Weisel K, Yu X, Donahue C, Acosta J, Peluso T, Dimopoulos M. Richardson P, et al. Among authors: galli m. Eur J Haematol. 2025 Jan 8. doi: 10.1111/ejh.14365. Online ahead of print. Eur J Haematol. 2025. PMID: 39777934
2,066 results